Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat.

Chen H, Luo B, Yang X, Yang X, Xiong J, Liu Z, Jiang M, Shi R, Yan C, Wu Y, Zhang Z

Journal of neuroimmunology28 Jan 2014Cited by 18 (Europe PMC)

PMID24518674DOI10.1016/j.jneuroim.2014.01.006PepBankPUB-24518674

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study18

18 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In EAE Lewis rats, therapeutic ARA290 significantly reduced the severity of the clinical score.
In plain wordsIn rats with a model of multiple sclerosis, ARA290 lowered the severity of disease signs.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseEAE clinical score severity
Study
ratn: not reported in source
Experimental autoimmune encephalomyelitis (EAE)
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
35, 70 μg/kg · intraperitoneal · Once daily, Day 7 to Day 18 or Day 9 to Day 19As given in this study (rat).
Source sentences
Summary
Therapeutic (from Day 7 to Day 18 or from Day 9 to Day 19) administration of ARA290 (35, 70 μg/kg, intra-peritoneal) to EAE rats once daily significantly reduced the severity and shortened the duration of clinical score
1 context sentence(design, population, supporting numbers)
Summary · context
Here we studied the therapeutic effects of ARA290 in experimental autoimmune encephalomyelitis (EAE) Lewis rats.
Report a problemFND-2451867401
02AnimalAnimal study (in vivo)Efficacy outcome
In EAE Lewis rats, therapeutic ARA290 shortened the duration of the clinical score.
In plain wordsIn rats with a model of multiple sclerosis, ARA290 shortened how long disease signs lasted.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseEAE clinical score duration
Study
ratn: not reported in source
Experimental autoimmune encephalomyelitis (EAE)
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
35, 70 μg/kg · intraperitoneal · Once daily, Day 7 to Day 18 or Day 9 to Day 19As given in this study (rat).
Source sentences
Summary
Therapeutic (from Day 7 to Day 18 or from Day 9 to Day 19) administration of ARA290 (35, 70 μg/kg, intra-peritoneal) to EAE rats once daily significantly reduced the severity and shortened the duration of clinical score
1 context sentence(design, population, supporting numbers)
Summary · context
Here we studied the therapeutic effects of ARA290 in experimental autoimmune encephalomyelitis (EAE) Lewis rats.
Report a problemFND-2451867402
03AnimalAnimal study (in vivo)Mechanism
In EAE rats, ARA290 reduced the accumulation of inflammatory cells in the spinal cord.
In plain wordsIn rats with a model of multiple sclerosis, ARA290 reduced the build-up of inflammatory cells in the spinal cord.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseInflammatory cell accumulation in spinal cord
Study
ratn: not reported in source
Experimental autoimmune encephalomyelitis (EAE)
Outcome group
Immune response · Immune and inflammation
Studied dose
35, 70 μg/kg · intraperitoneal · Once daily, Day 7 to Day 18 or Day 9 to Day 19As given in this study (rat).
Source sentences
Summary
reduced the accumulation of inflammatory cells in EAE spinal cords
2 context sentences(design, population, supporting numbers)
Summary · context
Therapeutic (from Day 7 to Day 18 or from Day 9 to Day 19) administration of ARA290 (35, 70 μg/kg, intra-peritoneal) to EAE rats once daily
Summary · context
Here we studied the therapeutic effects of ARA290 in experimental autoimmune encephalomyelitis (EAE) Lewis rats.
Report a problemFND-2451867403
04AnimalAnimal study (in vivo)Mechanism
In EAE rats, ARA290 suppressed IL-1β mRNA levels in the spinal cord.
In plain wordsIn rats with a model of multiple sclerosis, ARA290 lowered IL-1β gene activity, an inflammation signal, in the spinal cord.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseIL-1β mRNA in spinal cord
Study
ratn: not reported in source
Experimental autoimmune encephalomyelitis (EAE)
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
35, 70 μg/kg · intraperitoneal · Once daily, Day 7 to Day 18 or Day 9 to Day 19As given in this study (rat).
Source sentences
Summary
suppressed mRNA levels of interleukin-1β (IL-1β), IL-17, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), inducible nitric oxide synthase (iNOS), matrix metalloproteinase 9 (MMP9) and transcription factor T-bet in spinal cords of EAE rats
2 context sentences(design, population, supporting numbers)
Summary · context
Therapeutic (from Day 7 to Day 18 or from Day 9 to Day 19) administration of ARA290 (35, 70 μg/kg, intra-peritoneal) to EAE rats once daily
Summary · context
Here we studied the therapeutic effects of ARA290 in experimental autoimmune encephalomyelitis (EAE) Lewis rats.
Report a problemFND-2451867404
05AnimalAnimal study (in vivo)Mechanism
In EAE rats, ARA290 suppressed IL-17 mRNA levels in the spinal cord.
In plain wordsIn rats with a model of multiple sclerosis, ARA290 lowered IL-17 gene activity, an inflammation signal, in the spinal cord.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseIL-17 mRNA in spinal cord
Study
ratn: not reported in source
Experimental autoimmune encephalomyelitis (EAE)
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
35, 70 μg/kg · intraperitoneal · Once daily, Day 7 to Day 18 or Day 9 to Day 19As given in this study (rat).
Source sentences
Summary
suppressed mRNA levels of interleukin-1β (IL-1β), IL-17, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), inducible nitric oxide synthase (iNOS), matrix metalloproteinase 9 (MMP9) and transcription factor T-bet in spinal cords of EAE rats
2 context sentences(design, population, supporting numbers)
Summary · context
Therapeutic (from Day 7 to Day 18 or from Day 9 to Day 19) administration of ARA290 (35, 70 μg/kg, intra-peritoneal) to EAE rats once daily
Summary · context
Here we studied the therapeutic effects of ARA290 in experimental autoimmune encephalomyelitis (EAE) Lewis rats.
Report a problemFND-2451867405
06AnimalAnimal study (in vivo)Mechanism
In EAE rats, ARA290 suppressed TNF-α mRNA levels in the spinal cord.
In plain wordsIn rats with a model of multiple sclerosis, ARA290 lowered TNF-α gene activity, an inflammation signal, in the spinal cord.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseTNF-α mRNA in spinal cord
Study
ratn: not reported in source
Experimental autoimmune encephalomyelitis (EAE)
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
35, 70 μg/kg · intraperitoneal · Once daily, Day 7 to Day 18 or Day 9 to Day 19As given in this study (rat).
Source sentences
Summary
suppressed mRNA levels of interleukin-1β (IL-1β), IL-17, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), inducible nitric oxide synthase (iNOS), matrix metalloproteinase 9 (MMP9) and transcription factor T-bet in spinal cords of EAE rats
2 context sentences(design, population, supporting numbers)
Summary · context
Therapeutic (from Day 7 to Day 18 or from Day 9 to Day 19) administration of ARA290 (35, 70 μg/kg, intra-peritoneal) to EAE rats once daily
Summary · context
Here we studied the therapeutic effects of ARA290 in experimental autoimmune encephalomyelitis (EAE) Lewis rats.
Report a problemFND-2451867406
07AnimalAnimal study (in vivo)Mechanism
In EAE rats, ARA290 suppressed IFN-γ mRNA levels in the spinal cord.
In plain wordsIn rats with a model of multiple sclerosis, ARA290 lowered IFN-γ gene activity, an inflammation signal, in the spinal cord.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseIFN-γ mRNA in spinal cord
Study
ratn: not reported in source
Experimental autoimmune encephalomyelitis (EAE)
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
35, 70 μg/kg · intraperitoneal · Once daily, Day 7 to Day 18 or Day 9 to Day 19As given in this study (rat).
Source sentences
Summary
suppressed mRNA levels of interleukin-1β (IL-1β), IL-17, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), inducible nitric oxide synthase (iNOS), matrix metalloproteinase 9 (MMP9) and transcription factor T-bet in spinal cords of EAE rats
2 context sentences(design, population, supporting numbers)
Summary · context
Therapeutic (from Day 7 to Day 18 or from Day 9 to Day 19) administration of ARA290 (35, 70 μg/kg, intra-peritoneal) to EAE rats once daily
Summary · context
Here we studied the therapeutic effects of ARA290 in experimental autoimmune encephalomyelitis (EAE) Lewis rats.
Report a problemFND-2451867407
08AnimalAnimal study (in vivo)Mechanism
In EAE rats, ARA290 suppressed iNOS mRNA levels in the spinal cord.
In plain wordsIn rats with a model of multiple sclerosis, ARA290 lowered iNOS gene activity, an inflammation signal, in the spinal cord.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseiNOS mRNA in spinal cord
Study
ratn: not reported in source
Experimental autoimmune encephalomyelitis (EAE)
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
35, 70 μg/kg · intraperitoneal · Once daily, Day 7 to Day 18 or Day 9 to Day 19As given in this study (rat).
Source sentences
Summary
suppressed mRNA levels of interleukin-1β (IL-1β), IL-17, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), inducible nitric oxide synthase (iNOS), matrix metalloproteinase 9 (MMP9) and transcription factor T-bet in spinal cords of EAE rats
2 context sentences(design, population, supporting numbers)
Summary · context
Therapeutic (from Day 7 to Day 18 or from Day 9 to Day 19) administration of ARA290 (35, 70 μg/kg, intra-peritoneal) to EAE rats once daily
Summary · context
Here we studied the therapeutic effects of ARA290 in experimental autoimmune encephalomyelitis (EAE) Lewis rats.
Report a problemFND-2451867408
09AnimalAnimal study (in vivo)Mechanism
In EAE rats, ARA290 suppressed MMP9 mRNA levels in the spinal cord.
In plain wordsIn rats with a model of multiple sclerosis, ARA290 lowered MMP9 gene activity, a tissue-damage signal, in the spinal cord.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseMMP9 mRNA in spinal cord
Study
ratn: not reported in source
Experimental autoimmune encephalomyelitis (EAE)
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
35, 70 μg/kg · intraperitoneal · Once daily, Day 7 to Day 18 or Day 9 to Day 19As given in this study (rat).
Source sentences
Summary
suppressed mRNA levels of interleukin-1β (IL-1β), IL-17, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), inducible nitric oxide synthase (iNOS), matrix metalloproteinase 9 (MMP9) and transcription factor T-bet in spinal cords of EAE rats
2 context sentences(design, population, supporting numbers)
Summary · context
Therapeutic (from Day 7 to Day 18 or from Day 9 to Day 19) administration of ARA290 (35, 70 μg/kg, intra-peritoneal) to EAE rats once daily
Summary · context
Here we studied the therapeutic effects of ARA290 in experimental autoimmune encephalomyelitis (EAE) Lewis rats.
Report a problemFND-2451867409
10AnimalAnimal study (in vivo)Mechanism
In EAE rats, ARA290 suppressed mRNA levels of the transcription factor T-bet in the spinal cord.
In plain wordsIn rats with a model of multiple sclerosis, ARA290 lowered T-bet gene activity, an immune-cell signal, in the spinal cord.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseT-bet mRNA in spinal cord
Study
ratn: not reported in source
Experimental autoimmune encephalomyelitis (EAE)
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
35, 70 μg/kg · intraperitoneal · Once daily, Day 7 to Day 18 or Day 9 to Day 19As given in this study (rat).
Source sentences
Summary
suppressed mRNA levels of interleukin-1β (IL-1β), IL-17, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), inducible nitric oxide synthase (iNOS), matrix metalloproteinase 9 (MMP9) and transcription factor T-bet in spinal cords of EAE rats
2 context sentences(design, population, supporting numbers)
Summary · context
Therapeutic (from Day 7 to Day 18 or from Day 9 to Day 19) administration of ARA290 (35, 70 μg/kg, intra-peritoneal) to EAE rats once daily
Summary · context
Here we studied the therapeutic effects of ARA290 in experimental autoimmune encephalomyelitis (EAE) Lewis rats.
Report a problemFND-2451867410
11AnimalAnimal study (in vivo)Mechanism
In EAE rats, ARA290 treatment reduced the helper T cell number in lymph nodes.
In plain wordsIn rats with a model of multiple sclerosis, ARA290 reduced the number of helper T cells in lymph nodes.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseHelper T cell number in lymph nodes
Study
ratn: not reported in source
Experimental autoimmune encephalomyelitis (EAE)
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Furthermore, ARA290 treatment reduced the helper T cell number in lymph nodes and circulation in EAE.
1 context sentence(design, population, supporting numbers)
Summary · context
Here we studied the therapeutic effects of ARA290 in experimental autoimmune encephalomyelitis (EAE) Lewis rats.
Report a problemFND-2451867411
12AnimalAnimal study (in vivo)Mechanism
In EAE rats, ARA290 treatment reduced the helper T cell number in the circulation.
In plain wordsIn rats with a model of multiple sclerosis, ARA290 reduced the number of helper T cells in the blood.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseHelper T cell number in circulation
Study
ratn: not reported in source
Experimental autoimmune encephalomyelitis (EAE)
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Furthermore, ARA290 treatment reduced the helper T cell number in lymph nodes and circulation in EAE.
1 context sentence(design, population, supporting numbers)
Summary · context
Here we studied the therapeutic effects of ARA290 in experimental autoimmune encephalomyelitis (EAE) Lewis rats.
Report a problemFND-2451867412
13AnimalAnimal study (in vivo)Mechanism
In EAE rats, ARA290 altered the cytokine milieu to favor Th2 polarization in lymph nodes.
In plain wordsIn rats with a model of multiple sclerosis, ARA290 shifted immune signals toward Th2 cells in lymph nodes.
Peptide
Cibinetide (ARA-290)
Outcome
IncreaseTh2 cell polarization in EAE lymph nodes
Study
ratn: not reported in source
Experimental autoimmune encephalomyelitis (EAE)
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
In addition, ARA290 altered the cytokine milieu to favor the polarization of Th2 and regulatory T (Treg) cells but suppressed the polarization of Th1 and Th17 cells in EAE lymph nodes.
1 context sentence(design, population, supporting numbers)
Summary · context
Here we studied the therapeutic effects of ARA290 in experimental autoimmune encephalomyelitis (EAE) Lewis rats.
Report a problemFND-2451867415
14AnimalAnimal study (in vivo)Mechanism
In EAE rats, ARA290 altered the cytokine milieu to favor regulatory T (Treg) cell polarization in lymph nodes.
In plain wordsIn rats with a model of multiple sclerosis, ARA290 shifted immune signals toward regulatory T cells in lymph nodes.
Peptide
Cibinetide (ARA-290)
Outcome
IncreaseTreg cell polarization in EAE lymph nodes
Study
ratn: not reported in source
Experimental autoimmune encephalomyelitis (EAE)
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
In addition, ARA290 altered the cytokine milieu to favor the polarization of Th2 and regulatory T (Treg) cells but suppressed the polarization of Th1 and Th17 cells in EAE lymph nodes.
1 context sentence(design, population, supporting numbers)
Summary · context
Here we studied the therapeutic effects of ARA290 in experimental autoimmune encephalomyelitis (EAE) Lewis rats.
Report a problemFND-2451867416
15AnimalAnimal study (in vivo)Mechanism
In EAE rats, ARA290 suppressed Th1 cell polarization in lymph nodes.
In plain wordsIn rats with a model of multiple sclerosis, ARA290 reduced the shift toward inflammatory Th1 cells in lymph nodes.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseTh1 cell polarization in EAE lymph nodes
Study
ratn: not reported in source
Experimental autoimmune encephalomyelitis (EAE)
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
In addition, ARA290 altered the cytokine milieu to favor the polarization of Th2 and regulatory T (Treg) cells but suppressed the polarization of Th1 and Th17 cells in EAE lymph nodes.
1 context sentence(design, population, supporting numbers)
Summary · context
Here we studied the therapeutic effects of ARA290 in experimental autoimmune encephalomyelitis (EAE) Lewis rats.
Report a problemFND-2451867417
16AnimalAnimal study (in vivo)Mechanism
In EAE rats, ARA290 suppressed Th17 cell polarization in lymph nodes.
In plain wordsIn rats with a model of multiple sclerosis, ARA290 reduced the shift toward inflammatory Th17 cells in lymph nodes.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseTh17 cell polarization in EAE lymph nodes
Study
ratn: not reported in source
Experimental autoimmune encephalomyelitis (EAE)
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
In addition, ARA290 altered the cytokine milieu to favor the polarization of Th2 and regulatory T (Treg) cells but suppressed the polarization of Th1 and Th17 cells in EAE lymph nodes.
1 context sentence(design, population, supporting numbers)
Summary · context
Here we studied the therapeutic effects of ARA290 in experimental autoimmune encephalomyelitis (EAE) Lewis rats.
Report a problemFND-2451867418
17LabIn vitro (cells)Activity measurement
In vitro, ARA290 dose-dependently inhibited antigen-specific lymphocyte proliferation.
In plain wordsIn lab tests, ARA290 reduced the growth of antigen-specific immune cells, more so at higher doses.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseAntigen-specific lymphocyte proliferation
Study
n: not reported in source
In vitro lymphocyte proliferation assay
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
ARA290 dose-dependently inhibited antigen specific- and antigen non-specific-lymphocyte proliferation as well.
Report a problemFND-2451867413
18LabIn vitro (cells)Activity measurement
In vitro, ARA290 dose-dependently inhibited antigen non-specific lymphocyte proliferation.
In plain wordsIn lab tests, ARA290 reduced the growth of immune cells that were not antigen-specific, more so at higher doses.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseAntigen non-specific lymphocyte proliferation
Study
n: not reported in source
In vitro lymphocyte proliferation assay
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
ARA290 dose-dependently inhibited antigen specific- and antigen non-specific-lymphocyte proliferation as well.
Report a problemFND-2451867414

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.